Navigation Links
RBC Life Sciences' 2008 Net Sales Increase 13 Percent as Its Nutritional Supplements and Medical Products Brands See Continued Growth
Date:2/25/2009

IRVING, Texas, Feb. 25 /PRNewswire-FirstCall/ -- (OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, announced today that 2008 net sales increased 13 percent year over year as the company continued its domestic and international growth.

The company reported net sales of $30.4 million for the year ended December 31, 2008, compared to $27 million during the same period in 2007. It also reported net earnings of $1.62 million, or $0.07 per diluted share, in 2008 compared to net earnings of $1.69 million, or $0.08 per diluted share, in 2007.

"In 2008, RBC Life Sciences continued the surge in growth that the company witnessed in 2007, when the firm produced record-setting earnings," said President and CEO John W. Price. "Sales generated by our international licensees grew 18 percent year over year while sales generated by our medical products brand, MPM Medical, Inc., grew 41 percent during that time. This growth is occurring at the same time that we are beginning to see good gains in our domestic, independent sales force."

Mr. Price, who was promoted to CEO last month, began laying the framework in early 2008 for increased domestic and international growth across the company's nutritional supplements and medical products brands. In addition to hiring a sales director, communications director, science and technology director and a new vice president of marketing, Mr. Price recruited a strategic-growth veteran to the board of directors.

With international sales running strongly, Mr. Price redoubled the company's focus on rebuilding the independent Associate base responsible for driving domestic sales of nutritional supplements. Since launching the first phase of this effort on November 1, more than 1,100 new Associates have joined RBC Life Sciences. The second phase of the rebuilding effort will include revising the Associate compensation system to make it one of the industry's most-rewarding commission plans.

Mr. Price said that 2008 net earnings were affected by improvements to RBC Life Sciences headquarters' facility and upgrades to its operational infrastructure.

About RBC Life SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange

                                RBC Life Sciences, Inc.
                             Summary Results of Operations
                         (in thousands, except per share data)
                                      (unaudited)

                                                   Years Ended December 31,
                                                     2008           2007

     Net sales                                   $  30,409     $   27,029
     Gross profit                                   15,494         14,899
     Operating profit                                2,852          2,899
     Earnings before income taxes                    2,677          2,689
     Provision for income taxes                      1,061            997
     Net earnings                                    1,616          1,692

     Earnings per share - basic                  $    0.08     $     0.08
     Earnings per share - diluted                     0.07           0.08

     Weighted average shares outstanding -
      basic                                         21,465         20,396
     Weighted average shares outstanding -
      diluted                                       22,839         22,206

                                 RBC Life Sciences, Inc.
                                Condensed Balance Sheets
                                     (in thousands)
                                      (unaudited)

                                                  December 31,    December 31,
                                                      2008           2007
     Assets
     Cash and cash equivalents                  $     4,973     $    6,369
     Inventories                                      5,707          4,725
     Other current assets                             2,245          1,334
       Total current assets                          12,925         12,428
     Other assets                                     6,841          6,730
       Total assets                                 $19,766     $   19,158

     Liabilities and shareholders' equity
     Accounts payable and accrued liabilities   $     3,228     $    4,431
     Deferred revenue                                 4,279          4,323
     Other current liabilities                          144            136
       Total current liabilities                      7,651          8,890
     Other liabilities                                2,728          2,690
     Shareholders' equity                             9,387          7,578
       Total liabilities and shareholders'
        equity                                  $    19,766     $   19,158


'/>"/>
SOURCE RBC Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caliper Life Sciences Fourth Quarter 2008 Financial Results Conference Call Notice
2. Breathe California of Sacramento-Emigrant Trails Fighting to Keep Hackademy Awards Name in Trademark Action Brought By Academy of Motion Picture Arts and Sciences
3. HUYA Bioscience International Announces Collaboration Agreement With the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
4. Frost & Sullivan: Australian Pharmaceuticals and Life Sciences IT Market Is Still Growing
5. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
6. Accordent Delivers Medical Lecture Capture Platform for University of Texas Health Sciences Center
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
8. Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas
9. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
10. Introducing HEAL-WA--New Initiative Brings Evidence-Based Health Sciences Information to Health Professionals in Washington State
11. Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology: